1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Scancell and ImmuneRegen look at combining vaccine technologies

 
• By Eleanor Malone

UK therapeutic cancer vaccine developer Scancell Holdings and ImmuneRegen BioSciences are to investigate whether their technologies could be combined to develop improved product efficacy.

UK therapeutic cancer vaccine developer Scancell Holdings and ImmuneRegen BioSciences are to investigate whether their technologies could be combined to develop improved product efficacy.

They will look for potential synergies between Scancell's ImmunoBody technology, which consists of a human antibody or fusion protein engineered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Phase III Success For AiCuris’s Herpes Simplex Treatment

 
• By Andrew McConaghie

The German company is now gearing up for a US filing for a product that overcomes drug resistance issues in herpes simplex, and which it believes could transform its business.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment

The company announced Phase IIb results for the RSV drug that showed positive data across multiple key secondary endpoints, some of which could serve as a primary endpoint in Phase III.

Having Steadied GSK’s Ship, Walmsley To Step Down As Chief

 
• By Kevin Grogan

Chief commercial officer Luke Miels to take over in 'seamless succession'.

More from Therapeutic Category

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 
• By Alaric DeArment

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By Kevin Grogan

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.